Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

disease progression

- PMLiVE

Keytruda cleared in Europe for lung cancer

New second-line indication for Merck’s drug puts it in direct competition with BMS’ Opdivo

EU flag

EU proposes reforms to make first-in-human trials safer

New guideline revision paper “takes into account lessons learnt” from fatal Bial trial

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

- PMLiVE

The Netherlands leads Europe for future health

And benchmarking report finds UAE best placed to meet healthcare challenges

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

EU flag

EC approves Bial’s Parkinson’s disease therapy

Ongentys will be given a phase roll-out in 2016 and 2017

- PMLiVE

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant

- PMLiVE

Amgen’s Kyprolis wins new indication in Europe

Regulators have handed the treatment a less restrictive licence in multiple myeloma 

- PMLiVE

Connected Healthcare

Digital technologies are bringing healthcare professionals (HCPs) and their patients ever closer, and the potential benefits of this type of engagement seem to be many.

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

Gilead Sciences

Gilead gets EU nod for TAF-based triple therapy for HIV

Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity

- PMLiVE

Achieving the NHS’s vision through service redesign and pathway efficiencies

Technology and data sharing are at the heart of new NHS vanguard

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links